Abstract

This pharmaceutical composition is for treating human papilloma virus (HPV) tested-positive cancer or an HPV pretested-positive cancer pathological change gene, and includes: Cas guide RNA or a nucleic acid molecule encoding the same; and a Cas9 nickase or a nucleic acid molecule encoding the same. The Cas guide RNA or the nucleic acid molecule encoding the same includes a pair of specific Cas guide RNA or a pair of nucleic acid molecules encoding the same, or a combination of such pairs.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 35/761 - Adenovirus
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/861 - Adenoviral vectors

Abstract

Provided is a nucleoside represented by formula (1). [In formula (1): R1represents a hydroxyl group, a hydroxyl group in which the hydrogen atom is substituted by an alkyl or alkenyl group, or a protected hydroxyl group; R2nnR5R6(wherein n represents 0 or 1, and R5and R6are the same as or different from each other and represent any of a hydrogen atom, a hydroxyl group, a protected hydroxyl group, a mercapto group, a protected mercapto group, a lower alkoxy group, a cyano lower alkoxy group, an amino group or a substituted amino group, provided that when n is 1, then R5and R6cannot both be hydrogen atoms); R3represents a hydrogen atom, a protecting group of the hydroxyl group, a phosphate group, a protected phosphate group or a phosphorothioate group; R4represents a hydroxyl group, a protected hydroxyl group, an azide group or NHR7; R7 represents a hydrogen atom or a protecting group of the amino group; and B represents a purine base or a pyrimidine base.]

IPC Classes  ?

• C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
• C07H 19/167 - Purine radicals with ribosyl as the saccharide radical
• C07H 19/173 - Purine radicals with 2-deoxyribosyl as the saccharide radical
• C07H 23/00 - Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A compound represented by the general formula (I) given below or a pharmacologically acceptable salt thereof has been found to have a strong G9a inhibitory effect. The compound (I) or the pharmacologically acceptable salt thereof inhibits G9a and thereby has high usefulness for the treatment, prevention or suppression of various pathological conditions (proliferative disease such as cancer, β-globin abnormality, fibrosis, pain, neurodegenerative disease, Prader-Willi syndrome, malaria, viral infection, myopathy, autism, etc.). A compound represented by the general formula (I) given below or a pharmacologically acceptable salt thereof has been found to have a strong G9a inhibitory effect. The compound (I) or the pharmacologically acceptable salt thereof inhibits G9a and thereby has high usefulness for the treatment, prevention or suppression of various pathological conditions (proliferative disease such as cancer, β-globin abnormality, fibrosis, pain, neurodegenerative disease, Prader-Willi syndrome, malaria, viral infection, myopathy, autism, etc.).

IPC Classes  ?

• C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems

Abstract

Provided are a protective agent, a surfactant composition, a composition for blood sugar level control, an autophagy inducing agent, a stain for mycobacteria, or a protein extraction agent characterized by containing a compound represented by general formula (1).

IPC Classes  ?

• C12P 19/12 - Disaccharides
• A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07H 5/06 - Aminosugars
• C07H 15/12 - Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of a saccharide radical
• C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
• C12N 1/20 - BacteriaCulture media therefor
• C12P 19/44 - Preparation of O-glycosides, e.g. glucosides

Abstract

The following are provided: a novel adenovirus vector having a shortened backbone; a nucleic acid vector expressing five or more Cas guide RNA; a nucleic acid vector containing a Cas protein-coding gene and a Cas guide RNA expression unit; a composition for genome editing containing these vectors; and a gene therapeutic method using these.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/22 - Ribonucleases

Abstract

It was found that a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof has potent G9a inhibitory activity. Because of the ability to inhibit G9a, the compound (I) or a pharmaceutically acceptable salt thereof is highly useful in treatment, prevention or suppression of a variety of diseases (including proliferative diseases such as cancer, ß-globin abnormalities, fibrosis, pain, neurodegenerative diseases, Prader-Willi syndrome, malaria, viral infections, myopathy, and autism).

IPC Classes  ?

• C07K 5/078 - Dipeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 31/12 - Antivirals
• A61P 33/06 - Antimalarials
• A61P 35/00 - Antineoplastic agents
• C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/10 - Spiro-condensed systems
• C07K 5/06 - Dipeptides
• C12N 9/10 - Transferases (2.)

Abstract

It was found that a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof has potent G9a inhibitory activity. Because of the ability to inhibit G9a, the compound (I) or a pharmaceutically acceptable salt thereof is highly useful in treatment, prevention or suppression of a variety of diseases (including proliferative diseases such as cancer, β-globin abnormalities, fibrosis, pain, neurodegenerative diseases, Prader-Willi syndrome, malaria, viral infections, myopathy, and autism).

IPC Classes  ?

• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/12 - Antivirals
• A61P 33/06 - Antimalarials
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 209/96 - Spiro-condensed ring systems
• C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• C07D 487/10 - Spiro-condensed systems
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

Abstract

A catalyst represented by General Formula (1) below: 14 each independently represent a hydrogen atom or a substituent.

IPC Classes  ?

• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• C07F 5/05 - Cyclic compounds having at least one ring containing boron but no carbon in the ring

Abstract

A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.

IPC Classes  ?

• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• C07H 15/224 - Cyclohexane rings, substituted by at least two nitrogen atoms with only one saccharide radical directly attached to the cyclohexane rings, e.g. destomycin, fortimicin, neamine
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to: a novel adenovirus vector that has a shortened backbone; a nucleic acid vector that expresses 5 or more Cas guide RNAs; a nucleic acid vector that comprises a Cas protein and a Cas guide RNA-expressing unit; and a composition for editing a genome that comprises these vectors; and a method for gene therapy using same.

IPC Classes  ?

• C12N 15/861 - Adenoviral vectors
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/863 - Poxviral vectors, e.g. vaccinia virus
• C12N 15/866 - Baculoviral vectors
• C12N 15/867 - Retroviral vectors
• C12N 15/869 - Herpesviral vectors

Abstract

Disclosed are: a method for manufacturing a compound (5-epi-4"-N-(L-isoceryl)apramycin) and 5-epiapramycin; and an intermediate used for said method. The method of the present invention is useful in that the compound (5-epi-4"-N-(L-isoceryl)apramycin) can be efficiently and completely produced.

IPC Classes  ?

• C07H 15/224 - Cyclohexane rings, substituted by at least two nitrogen atoms with only one saccharide radical directly attached to the cyclohexane rings, e.g. destomycin, fortimicin, neamine
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 31/04 - Antibacterial agents

Abstract

Provided is a catalyst represented by general formula (1). In general formula (1), R1-R14 each independently represent a hydrogen atom or a substituent.

IPC Classes  ?

• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 31/40 - Regeneration or reactivation
• C07B 53/00 - Asymmetric syntheses
• C07B 61/00 - Other general methods
• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• C07C 231/16 - Preparation of optical isomers
• C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
• C07C 233/13 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
• C07C 233/22 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
• C07C 233/29 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
• C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
• C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• C07D 333/38 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

A catalyst including: neodymium; sodium; and a ligand, which is a compound expressed by Structural Formula (1) below, wherein the neodymium and the ligand form a complex at a molar ratio of 1:2 (neodymium:ligand):

IPC Classes  ?

• B01J 31/00 - Catalysts comprising hydrides, coordination complexes or organic compounds
• C07C 201/00 - Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
• C07C 205/00 - Compounds containing nitro groups bound to a carbon skeleton
• C07C 237/00 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
• B01J 31/22 - Organic complexes
• B01J 37/04 - Mixing
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 205/16 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
• C07C 205/32 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 205/54 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• C07B 61/00 - Other general methods

Abstract

A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.

IPC Classes  ?

• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• C07H 15/224 - Cyclohexane rings, substituted by at least two nitrogen atoms with only one saccharide radical directly attached to the cyclohexane rings, e.g. destomycin, fortimicin, neamine
• A61P 31/04 - Antibacterial agents

Abstract

Disclosed are: a compound represented by general formula (I), a pharmaceutically acceptable salt thereof or a solvate of the same; a medicinal composition comprising the same; use of the same for preventing or treating infectious diseases; and a method for preventing or treating infectious diseases, said method comprising using the same. The compound represented by general formula (I), which has an antibacterial activity against both of gram-positive bacteria and gram-negative bacteria, is useful for preventing or treating infectious diseases caused by these bacteria.

IPC Classes  ?

• C07H 5/06 - Aminosugars
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61P 17/00 - Drugs for dermatological disorders
• A61P 27/02 - Ophthalmic agents
• A61P 27/16 - Otologicals
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/04 - Antibacterial agents

Abstract

Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.

IPC Classes  ?

• C07D 215/233 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
• A61P 31/04 - Antibacterial agents
• A61P 35/00 - Antineoplastic agents

Abstract

The purpose of the present invention is to provide a method capable of analyzing an SMN protein nuclear body that serves as a more highly reliable biomarker. The method according to the present invention is a method for analyzing the expression of an SMN protein nuclear body, and comprises the steps of: labeling at least one surface antigen marker for blood-derived nucleated cells with at least one labeling antibody in a sample containing the nucleated cells; labeling the SMN protein in the nucleated cells; labeling the nuclei of the nucleated cells; selecting one cell mass from among multiple cell masses of the nucleated cells, the multiple cell masses being cell masses in which the nucleus and the SMN protein are labeled and which have been classified on the basis of the surface antigen marker labeled with the labeling antibody or the like; and subjecting the selected cell mass to analysis on the expression of the SMN protein nuclear body on the basis of the labeling of the SMN protein. The method involves carrying out imaging flow cytometry using an objective lens at a specific magnification.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/536 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

A method for producing an optically active α-trifluoromethyl-β-amino acid derivative, the method including: allowing a compound represented by the following General Formula (1) and a compound represented by the following General Formula (2) to react in the presence of a copper-optically active phosphine complex obtained from a copper compound and an optically active phosphine compound, to thereby obtain an optically active α-trifluoromethyl-β-amino acid derivative represented by the following General Formula (3):

IPC Classes  ?

• C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• B01J 31/24 - Phosphines

Abstract

Provided is a catalyst represented by general formula (1), where R1-R16 in the general formula (1) individually represent a hydrogen atom or a substituent independently of each other.

IPC Classes  ?

• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 233/13 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
• C07C 233/29 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
• C07C 233/59 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
• C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• C07C 235/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• C07D 213/40 - Acylated substituent nitrogen atom
• C07D 295/192 - Radicals derived from carboxylic acids from aromatic carboxylic acids
• C07D 333/38 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07B 61/00 - Other general methods
• C07F 5/05 - Cyclic compounds having at least one ring containing boron but no carbon in the ring

Abstract

Helicobacter pylori agent each containing the above compound.

IPC Classes  ?

• C07D 215/233 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4

Abstract

This catalyst contains neodymium, sodium, and a ligand which is a compound represented by structural formula (1), wherein the neodymium and the ligand form a complex at a molar ratio of 1 : 2 (neodymium : ligand).

IPC Classes  ?

• B01J 31/22 - Organic complexes
• B01J 37/04 - Mixing
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 205/16 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
• C07C 205/32 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 205/54 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07B 61/00 - Other general methods
• C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Abstract

Provided is a method for efficiently producing a compound represented by formula II, namely (2S)-2-hydroxyarbekacin or a salt thereof from (2S)-2-hydroxydibekacin represented by formula I or a salt thereof, which is characterized by using a compound represented by formula III or a salt thereof as a synthetic intermediate. (In the formulae, R1 represents an optionally substituted alkyloxycarbonyl group or an optionally substituted arylalkyloxycarbonyl group.)

IPC Classes  ?

• C07H 15/234 - Cyclohexane rings, substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2

Abstract

Provided is a method for stably producing (2S)-2-hydroxydibekacin, said method being characterized by the use of 2-hydroxykanamycin C or 2-hydroxykanamycin B as a starting material or synthetic intermediate.

IPC Classes  ?

• C07H 15/234 - Cyclohexane rings, substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
• A61P 31/04 - Antibacterial agents
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• C07B 51/00 - Introduction of protecting groups or activating groups, not provided for in groups
• C07B 61/00 - Other general methods

Abstract

Provided is a method for stably producing (2S)-2-hydroxydibekacin, said method being characterized by the use of 2-hydroxykanamycin C or 2-hydroxykanamycin B as a starting material or synthetic intermediate.

IPC Classes  ?

• C07H 15/234 - Cyclohexane rings, substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 31/04 - Antibacterial agents

Abstract

Provided is a method for determining the immune status of a patient after starting treatment using an anti-human immunodeficiency virus drug, said method including a detection step for detecting a transcript up to 200 bases from a transcription start point of human immunodeficiency virus RNA in peripheral blood mononuclear cells, and a step for evaluating whether the patient's immunity is in an activated state using the detection or non-detection of the transcript as an index.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Disclosed are: a compound represented by general formula (I), or a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt; a pharmaceutical composition containing the compound, the pharmaceutically acceptable salt or the solvate; a use of the compound, the pharmaceutically acceptable salt or the solvate for the prevention or treatment of infectious diseases; and a method for preventing or treating infectious diseases using the compound, the pharmaceutically acceptable salt or the solvate. The compound represented by general formula (I) has an antibacterial activity against both gram-positive bacteria and gram-negative bacteria, and is therefore useful for the prevention or treatment of infectious diseases induced by these bacteria.

IPC Classes  ?

• C07H 15/12 - Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of a saccharide radical
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 31/04 - Antibacterial agents
• C07H 15/234 - Cyclohexane rings, substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2

Abstract

Disclosed are: a compound represented by general formula (I), or a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt; a pharmaceutical composition containing the compound, the pharmaceutically acceptable salt or the solvate; a use of the compound, the pharmaceutically acceptable salt or the solvate for the prevention or treatment of infectious diseases; and a method for preventing or treating infectious diseases using the compound, the pharmaceutically acceptable salt or the solvate. The compound represented by general formula (I) has an antibacterial activity against both gram-positive bacteria and gram-negative bacteria, and is therefore useful for the prevention or treatment of infectious diseases induced by these bacteria.

IPC Classes  ?

• C07H 15/12 - Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of a saccharide radical
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 31/04 - Antibacterial agents
• C07H 15/234 - Cyclohexane rings, substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2

Abstract

This method for producing a compound represented by general formula (1) comprises a reaction step for reacting a compound represented by general formula (2) with a compound represented by general formula (3) in the presence of a catalyst containing an asymmetric ligand represented by general formula (A), to obtain the compound represented by general formula (1). However, in general formula (1) and general formula (2), R1 represents either a hydrogen atom or a protecting group for an amino group and R2 represents either a hydrogen atom or a protecting group for an amino group. In general formula (1) and general formula (3), R11 represents an optionally substituted aromatic group, R12 represents an optionally substituted aromatic group, and R13 represents either a hydrogen atom or a protecting group for an amino group. However, in general formula (A), R represents any one of an alkyl group having 1-6 carbon atoms, an aryl group, a substituted aryl group, an aralkyl group, and a ring-substituted aralkyl group.

IPC Classes  ?

• C07F 9/572 - Five-membered rings
• C07D 471/20 - Spiro-condensed systems

Abstract

A compound represented by structural formula (A) or (B); a method for producing the compound; a microorganism having an ability of producing the compound represented by the formula (A) or (B); and a compound-containing composition and an anti-cancer agent, each of which contains the compound.

IPC Classes  ?

• C12P 1/02 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using fungi
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61P 35/00 - Antineoplastic agents
• C07H 15/244 - Anthraquinone radicals, e.g. sennosides
• C12N 1/14 - Fungi Culture media therefor

Abstract

Provided is a cancer cell growth inhibitor, which includes at least one selected from the compounds represented by structural formulas (1) through (8), wherein the cancer cells are at least cancer cells that over-express wild epithelial growth factor receptor or cancer cells that express epithelial growth factor receptor mutant vIII.

IPC Classes  ?

• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61P 35/00 - Antineoplastic agents
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

An autophagy inducing agent that comprises at least one member selected from a compound represented by structural formula (A), a compound represented by structural formula (B), and a compound represented by structural formula (C).

IPC Classes  ?

• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 35/74 - Bacteria
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 39/06 - Free radical scavengers or antioxidants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a production method for an optically active α-trifluormethyl-β-amino acid derivative whereby: a compound indicated by general formula (1) and a compound indicated by general formula (2) are reacted in the presence of a copper-optically active phosphine complex comprising a copper compound and an optically active phosphine compound; and an optically active α-trifluormethyl-β-amino acid derivative indicated by general formula (3) is obtained.

IPC Classes  ?

• C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• B01J 31/22 - Organic complexes
• C07B 53/00 - Asymmetric syntheses
• C07B 57/00 - Separation of optically-active organic compounds
• C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
• C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• C07D 471/04 - Ortho-condensed systems
• C07B 61/00 - Other general methods

Abstract

Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.

IPC Classes  ?

• C07D 215/233 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4

Abstract

A catalyst, which is obtained by mixing a compound expressed by the following Structural Formula (1), a nitroalkane compound, a neodymium-containing compound, a sodium-containing compound, and a carbon structure:

IPC Classes  ?

• B01J 31/22 - Organic complexes
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 205/02 - Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 21/18 - Carbon
• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths

Abstract

A method for producing an optically active anti-1,2-nitroalkanol compound, the method including a supplying step for continuously supplying an aldehyde compound and a C2 or higher nitroalkane compound to a reaction container, a reaction step for reacting the aldehyde compound and the C2 or higher nitroalkane compound in the reaction container and obtaining an optically active anti-1,2-nitroalkanol compound, and a discharge step for continuously discharging the optically active anti-1,2-nitroalkanol compound from the reaction container, and the reaction container including a catalyst obtained by mixing a compound represented by structural formula (1), anitroalkane compound, a neodymium-containing compound, a sodium-containing compound, and a carbon structure.

IPC Classes  ?

• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 205/32 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07B 53/00 - Asymmetric syntheses
• C07B 61/00 - Other general methods

Abstract

The present invention provides compounds belonging to 3-acyloxyindole compounds or 3-acyl-4-hydroxycoumarin compounds, a tautomer or geometric isomer thereof, or a salt thereof and methods for producing the same, which compounds are useful as antibacterial agent and as therapeutic drugs against infectious diseases.

IPC Classes  ?

• C07D 209/34 - Oxygen atoms in position 2
• C07D 311/56 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3

Abstract

Provided is a method for detecting the expression of SMN protein, said method comprises: a step for labeling SMN protein in a sample, said sample containing nucleated cells derived from blood; a step for labeling the nuclei of the nucleated cells in the sample; a step for selecting cell masses wherein the nuclei of the nucleated cells and the SMN protein are labeled; and a step for detecting the expression of the SMN protein on the basis of the label bound to the SMN protein in the cell masses that are selected above.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

A method for manufacturing voriconazole, said method including: a step for converting a compound represented by general formula (1) into a compound represented by general formula (2); a step for converting the compound represented by general formula (2) into a compound represented by general formula (3); and a step for converting the compound represented by general formula (3) into voriconazole. In general formula (1), R1 represents either a hydrogen atom or a protecting group of a hydroxyl group, and R2 represents a halogen atom. In general formula (2), R3 and R4 each independently represent either a hydrogen atom or a protecting group of a hydroxyl group, and R5 represents a halogen atom. In general formula (3), X represents any of the divalent groups represented by the structural formulae.

IPC Classes  ?

• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 239/30 - Halogen atoms or nitro radicals
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

A manufacturing method for a compound represented by general formula (1), the method comprising a reaction process for reacting a compound represented by general formula (3) with a compound represented by general formula (4). general formula (1) In general formula (1), R1 and R2 represent either aliphatic groups that may have a substituent or aromatic groups that may have a substituent (provided R1 and R2 are different groups). R3 represents an aromatic group that may have a substituent. R4 represents either an aliphatic group that may have a substituent or an aromatic group that may have a substituent. general formula (3) In general formula (3), R1 and R2 represent either aliphatic groups that may have a substituent or aromatic groups that may have a substituent (provided R1 and R2 are different groups). R3 represents an aromatic group that may have a substituent. general formula (4) In general formula (4), R4 represents either an aliphatic group that may have a substituent or an aromatic group that may have a substituent.

IPC Classes  ?

• C07F 9/40 - Esters thereof
• C07F 9/53 - Organo-phosphine oxidesOrgano-phosphine sulfides
• C07B 61/00 - Other general methods

Abstract

A combined antibacterial agent for acid-fast bacteria that combines an activity inhibitor of WecA or an ortholog thereof, with an activity inhibitor of MurX or an ortholog thereof and/or an RNA synthesis inhibitor; a screening method for antibacterial agents for acid-fast bacteria; and an activity inhibitor of WecA or an ortholog thereof.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61P 31/04 - Antibacterial agents

Abstract

Provided are: a compound represented by structural formula (1); a production method therefor; a microorganism capable of producing said compound; and a compound-containing composition, an anticancer agent, and an anti-Helicobacter pylori agent which include said compound.

IPC Classes  ?

• C12P 17/12 - Nitrogen as only ring hetero atom containing a six-membered hetero ring
• A61K 31/47 - QuinolinesIsoquinolines
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 31/04 - Antibacterial agents
• A61P 35/00 - Antineoplastic agents
• C07D 215/58 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/365 - Nocardia

Abstract

Provided are: a compound represented by any one from among structural formulae (1) to (13); a production method therefor; and a compound-containing composition, an anticancer agent, and an anti-Helicobacter pylori agent which include said compound.

IPC Classes  ?

• C07D 215/22 - Oxygen atoms attached in position 2 or 4
• A61K 31/47 - QuinolinesIsoquinolines
• A61P 31/04 - Antibacterial agents
• A61P 35/00 - Antineoplastic agents

Abstract

A catalyst which is obtained by mixing a compound represented by structural formula (1), a nitroalkane compound, a neodymium-containing compound, a sodium-containing compound and a carbon structure.

IPC Classes  ?

• B01J 31/22 - Organic complexes
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 205/15 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07C 205/16 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
• C07C 205/26 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups and being further substituted by halogen atoms
• C07C 205/32 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07B 61/00 - Other general methods
• C07C 205/02 - Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07C 237/36 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Abstract

Provided are an anticancer agent containing ellagitannin, and a combination use anticancer agent in which the anticancer agent containing ellagitannin and an anticancer agent containing anthracycline are used in combination.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 35/00 - Antineoplastic agents
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Abstract

An E-cadherin binding agent containing GAPDH protein and/or analogous proteins, a protein synthesis inhibitor containing the E-cadherin binding agent, a cancer cell growth inhibiting drug containing E-cadherin binding agent and/or the protein synthesis inhibitor, and an antitumoral agent containing the cancer cell growth inhibitor.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 38/44 - Oxidoreductases (1)
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

A compound characterized in being represented by any of general formulae (1) to (5); a tautomer or a geometric isomer thereof; a salt of the compound, tautomer, or geometric isomer; and the like. (In the formulae, X1 represents a single bond or a C1-8 alkylene group; Y1 represents a single bond, -O-, -NHCO-, etc.; Z1 represents a C8-30 alkyl group optionally having a halogen atom; X2 represents a single bond, -CO-, etc.; Y2 represents a hydrogen atom or an optionally-substituted C1-30 hydrocarbon group; Z2 represents a C5-30 hydrocarbon group optionally having a halogen atom; X3 represents a single bond, or -NH-; Y3 represents -O-, -NH-, etc.; X4 represents a C1-8 alkylene group; Z represents a hydrogen atom, a halogen atom, a C1-6 alkoxy group, or a C1-20 hydrocarbon group; R1 represents an optionally-substituted C1-30 hydrocarbon group; and Z3 represents a halogen atom, a C1-6 alkoxy group, or a C1-20 hydrocarbon group).

IPC Classes  ?

• C07D 209/34 - Oxygen atoms in position 2
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/404 - Indoles, e.g. pindolol
• A61P 31/04 - Antibacterial agents
• C07D 311/56 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3

Abstract

A compound represented by general formula (1). In general formula (1), R1 represents either one of a protective group for a hydroxy group and a hydrogen atom, and R2 and R3 independently represent a protective group for an amino group.

IPC Classes  ?

• C07C 217/28 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
• C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
• C07C 215/10 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
• C07C 229/30 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
• C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 319/06 - 1,3-DioxanesHydrogenated 1,3-dioxanes not condensed with other rings
• C07B 61/00 - Other general methods

Abstract

A compound represented by general formula (I); a method for producing the compound; a microorganism capable of producing the compound; a pharmaceutical composition containing the compound; an anti-tumor agent comprising the pharmaceutical composition; and others. In general formula (I), X represents a group represented by general formula (IA) or general formula (IB). In general formula (IA) and general formula (IB), * represents a bond.

IPC Classes  ?

• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• A61K 35/74 - Bacteria
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• C12N 1/20 - BacteriaCulture media therefor
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12R 1/465 - Streptomyces

Abstract

A treatment agent for salt-containing organic waste liquid, the treatment agent including: Scuticociliatida, wherein the treatment agent treats salt-containing organic waste liquid; and a treatment method for salt-containing organic waste liquid, the treatment method including: bringing Scuticociliatida and salt-containing organic waste liquid into contact with each other to treat the salt-containing organic waste liquid.

IPC Classes  ?

• C02F 3/32 - Biological treatment of water, waste water, or sewage characterised by the animals or plants used, e.g. algae
• C02F 1/52 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities
• C02F 3/34 - Biological treatment of water, waste water, or sewage characterised by the microorganisms used
• B01D 21/01 - Separation of suspended solid particles from liquids by sedimentation using flocculating agents
• B01D 21/26 - Separation of sediment aided by centrifugal force
• C02F 103/32 - Nature of the water, waste water, sewage or sludge to be treated from the food or foodstuff industry, e.g. brewery waste waters

Abstract

　In order to provide an antibody that can detect a target molecules useful for cancer treatment or the like and that can specifically bind to said molecules, and an anti-cancer agent that uses said antibody as an active component, a comparison between prostate cancer cell lines (between LNCaP-CR cells and LNCaP cells) was carried out using SST-REX, and CXADR was identified as a molecule that is involved in tumorigenicity and the like. Furthermore, monoclonal antibodies against CXADR were produced, and because the monoclonal antibodies were found to exhibit anti-cancer activity, ADCC activity, CDC activity and the like, it was discovered that the antibody that binds to the epitope present at position 181-230 on human-derived CXADR protein exhibits an anti-cancer effect against prostate cancer cells, pancreatic cancer cells and colorectal cancer cells. It was also demonstrated that said antibody has ADCC activity and CDC activity. The structure of the variable region of the heavy and light chains of the antibody was successfully determined.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12N 15/02 - Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
• C12P 21/08 - Monoclonal antibodies

Abstract

Bacillus produces a thrombolytic enzyme which decomposes waste.

IPC Classes  ?

• C02F 3/34 - Biological treatment of water, waste water, or sewage characterised by the microorganisms used
• C12N 9/54 - Proteinases derived from bacteria bacteria being Bacillus
• B09B 3/00 - Destroying solid waste or transforming solid waste into something useful or harmless
• C12R 1/125 - Bacillus subtilis
• B09B 5/00 - Operations not covered by a single other subclass or by a single other group in this subclass

Abstract

Provided is a compound represented by general formula (1). (1) In general formula (1), R1 is either a protecting group for a hydroxyl group or a hydrogen atom. R2 is either a methyl group or an ethyl group.

IPC Classes  ?

• C07D 307/33 - Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
• B01J 31/24 - Phosphines
• C07C 323/12 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• C07C 381/12 - Sulfonium compounds
• C07D 301/02 - Synthesis of the oxirane ring
• C07D 303/22 - Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
• C07D 309/30 - Oxygen atoms, e.g. delta-lactones
• C07B 53/00 - Asymmetric syntheses
• C07B 61/00 - Other general methods

Abstract

A compound represented by structural formula (A) or a salt thereof. The compound or the salt thereof is produced suitably from a microorganism belonging to the genus Saccharothrix and can be used suitably as a prostaglandin production inhibitor.

IPC Classes  ?

• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 35/74 - Bacteria
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 1/20 - BacteriaCulture media therefor
• C12P 17/06 - Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
• C12R 1/01 - Bacteria or actinomycetales

Abstract

A tripropeptin derivative represented by general formula (1) or (2), or a pharmacologically acceptable salt thereof. In general formula (1), R1 represents an organic group having 1-20 carbon atoms. In general formula (2), R2 represents an organic group having 1-20 carbon atoms.

IPC Classes  ?

• C07K 11/02 - Depsipeptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof cyclic, e.g. valinomycins
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/04 - Antibacterial agents
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

Provided is a compound represented by general formula (1). Also provided is a method for producing a compound represented by formula (1) that comprises a reaction step for reacting a compound represented by general formula (2), a compound represented by general formula (3), and a compound represented by general formula (4). In general formulas (1) through (4), R1 is a protector group of a carboxyl group or a hydrogen atom; R2 and R3 are each independently a protector group of an amino group or a hydrogen atom; and R4 is a protector group of a carboxyl group or a hydrogen atom.

IPC Classes  ?

• C07C 229/30 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
• A61K 31/225 - Polycarboxylic acids
• A61P 31/12 - Antivirals
• C07C 227/10 - Formation of amino groups in compounds containing carboxyl groups with simultaneously increasing the number of carbon atoms in the carbon skeleton
• C07C 227/16 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
• C07C 227/32 - Preparation of optical isomers by stereospecific synthesis
• C07C 229/48 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
• C07C 269/04 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
• C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
• C07C 271/24 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07B 53/00 - Asymmetric syntheses
• C07B 61/00 - Other general methods

Abstract

Provided is the thioamide compound represented by general formula (1). In general formula (1): R1 represents -OR11 or -NR12R13; R2 and R3 each independently represent a protecting group of an amide group or a hydrogen atom; R11 represents a protecting group of a hydroxide group or a hydrogen atom; and R12 and R13 each independently represent a protecting group of an amino group or a hydrogen atom (moreover, R12 and R13 may together form a ring-structured protecting group).

IPC Classes  ?

• C07C 327/42 - Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 3/06 - Antihyperlipidemics
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
• C07B 61/00 - Other general methods

Abstract

A peptide comprising at least any one amino acid sequence selected from the amino acid sequences represented by SEQ ID NO:1 to SEQ ID NO:4 shown below. ALGDSLYGAASLN (SEQ ID NO:1) MTVDNPASTTNKDKLFSVWK (SEQ ID NO:2) PGAVPEK (SEQ ID NO:3) STKDLTTY (SEQ ID NO:4)

IPC Classes  ?

• C07K 14/105 - Poliovirus
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C12N 15/09 - Recombinant DNA-technology

Abstract

An agent for treating a salt-containing organic liquid waste, which contains at least a Scuticociliatida ciliate and can treat the salt-containing organic liquid waste; and a method for treating a salt-containing organic liquid waste, comprising an salt-containing organic liquid waste treatment step of bringing a Scuticociliatida ciliate into contact with the salt-containing organic liquid waste to thereby treat the salt-containing organic liquid waste.

IPC Classes  ?

• C02F 3/32 - Biological treatment of water, waste water, or sewage characterised by the animals or plants used, e.g. algae
• B01D 21/01 - Separation of suspended solid particles from liquids by sedimentation using flocculating agents
• C02F 1/52 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities

Abstract

Disclosed is a microorganism belonging to the genus Bacillus, which is characterized by being a strain that is selected from among Bacillus subtilis strain 104-1-3-1 (Accession No. NITE P-680) and strains induced therefrom and by producing a thrombolytic enzyme that decomposes waste.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• B09B 3/00 - Destroying solid waste or transforming solid waste into something useful or harmless
• C02F 1/00 - Treatment of water, waste water, or sewage
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/54 - Proteinases derived from bacteria bacteria being Bacillus

Abstract

A method for treating an individual infected with XDR-TB, the method including administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below:

IPC Classes  ?

• C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine

Abstract

A read through inducer for an immature termination codon formed by a nonsense mutation, which comprises a compound represented by structure formula (A); and a therapeutic agent for nonsense-mutation-type genetic diseases, which comprises the read through inducer.

IPC Classes  ?

• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61P 9/02 - Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07H 15/234 - Cyclohexane rings, substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2

Abstract

An antibacterial agent for drug-resistant bacteria, which comprises either nibomycin and/or a derivative thereof and is effective on drug-resistant bacteria each having resistance to at least one drug.

IPC Classes  ?

• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61P 31/04 - Antibacterial agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 498/16 - Peri-condensed systems

Abstract

A novel compound represented by general formula (1) and salts thereof, which are obtained by subjecting amycolamicin obtained from a microorganism belonging to the genus Amycolatopsis or a salt thereof to decomposition under acid conditions, and which exhibit inhibitory activity against cell proliferation. In general formula (1), R is a hydrogen atom or an alkyl group.

IPC Classes  ?

• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12P 17/10 - Nitrogen as only ring hetero atom

Abstract

Disclosed are: a compound represented by structural formula (1) or a pharmacologically acceptable salt thereof; a histone acetylase inhibitor; a nuclear receptor transcription activation inhibitor; a deuteromycetes belonging to the genus Penicillium, which can produce the compound; a process for producing the compound, which comprises a culturing step of culturing the microorganism and a collection step of collecting the compound from a culture produced in the culturing step; and others.

IPC Classes  ?

• A61K 36/06 - Fungi, e.g. yeasts
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/06 - Antipsoriatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 27/02 - Ophthalmic agents
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 241/18 - Oxygen or sulfur atoms
• C07K 5/027 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link in which at least a gamma-amino acid is involved, e.g. statine
• C12N 1/14 - Fungi Culture media therefor
• C12N 9/10 - Transferases (2.)
• C12P 1/02 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using fungi
• C12P 17/00 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms

Abstract

Disclosed are: a novel compound which has an excellent antibacterial activity against a wide variety of pathogenic bacteria including drug-resistant bacteria and bacteria causing pneumonia in domestic livestock, a tautomer of the compound, or a salt of the compound or the tautomer; a method for producing the compound, the tautomer or the salt; and others. Specifically disclosed are: a compound characterized by being represented by structural formula (1), a tautomer of the compound, or a salt of the compound or the tautomer; a method for producing the compound, the tautomer or the salt, which is characterized by culturing a microorganism belonging to the genus Amycolatopsis and capable of producing the compound, the tautomer or the salt to produce a culture, and collecting the compound, the tautomer or the salt from the culture; and others.

IPC Classes  ?

• C12P 17/16 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing two or more hetero rings
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61P 31/04 - Antibacterial agents
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C12N 1/20 - BacteriaCulture media therefor

Abstract

An anti-XDR-TB drug including a compound having a structure expressed by Structural Formula (1) below; an anti-MDR-TB drug including a compound having a structure expressed by Structural Formula (1) below; and a combination anti-tuberculosis drug including a drug containing a compound having a structure expressed by Structural Formula (1) below, and at least one anti-tuberculosis drug selected from an anti-tuberculosis drug containing rifampicin (RFP) and an anti-tuberculosis drug containing isonicotinic acid hydrazide (INH). (see formula 1)

IPC Classes  ?

• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 31/06 - Antibacterial agents for tuberculosis
• C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical

Abstract

Disclosed are: an anti-XDR-TB agent having excellent pharmacological efficacy against extremely drug-resistant tuberculosis bacteria; an anti-MDR-TB agent having excellent pharmacological efficacy against multi-drug-resistant tuberculosis bacteria; and a combined anti-tuberculous agent having excellent pharmacological efficacy against tuberculosis bacteria having susceptibility to existing anti-tuberculous agents. Specifically disclosed are: an anti-XDR-TB agent comprising a compound represented by structural formula (1); an anti-MDR-TB agent comprising a compound represented by structural formula (1); and a combined anti-tuberculous agent which comprises a combination of a pharmaceutical agent comprising a compound represented by structural formula (1) and at least one anti-tuberculous agent selected from an anti-tuberculous agent comprising rifampicin (RFP) and an anti-tuberculous agent comprising isonicotinic acid hydrazide (INH).

IPC Classes  ?

• C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

An anti-XDR-TB drug including a compound having a structure expressed by Structural Formula (1) below; an anti-MDR-TB drug including a compound haying a structure expressed by Structural Formula (1) below; and a combination anti-tuberculosis drug including a drug containing a compound having a structure expressed by Structural Formula (1) below, and at least one anti-tuberculosis drug selected from an anti-tuberculosis drug containing rifampicin (RFP) and an anti-tuberculosis drug containing isonicotinic acid hydrazide (INH). (see Structural Formula (1))

IPC Classes  ?

• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

Disclosed are: a novel compound having an excellent inhibitory activity against at least one of a neutral ceramidase and an alkaline ceramidase; a process for producing the compound; a novel microorganism capable of producing the novel compound; and a ceramidase inhibitor or a pharmaceutical composition comprising the novel compound. Specifically disclosed are: a compound characterized by being represented by structural formula (1); a process for producing the compound, which is characterized by comprising a culture step of culturing a microorganism belonging to the genus Penicillium and capable of producing the compound and a collection step of collecting the compound from a culture obtained in the culture step; and others.

IPC Classes  ?

• C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 36/06 - Fungi, e.g. yeasts
• A61P 17/00 - Drugs for dermatological disorders
• A61P 37/08 - Antiallergic agents
• C07D 493/04 - Ortho-condensed systems
• C12N 1/14 - Fungi Culture media therefor
• C12N 9/99 - Enzyme inactivation by chemical treatment

Abstract

Disclosed are: a novel compound which exhibits an excellent antibacterial activity against a wide variety of pathogenic bacteria including drug-resistant bacteria and plant-disease-causing bacteria, or exhibits an inhibitory activity against enzymes secreted from the bacteria, through the inhibition of the two-component regulatory systems of the bacteria; a method for producing the compound; a novel microorganism capable of producing the novel compound; and a compound-containing composition, an antibacterial agent, or an enzymatic activity inhibitor each utilizing the novel compound. Specifically disclosed are: a compound represented by the structural formula (1); a compound represented by the structural formula (2); a method for producing each of the compounds, which comprises a culture step of culturing a microorganism belonging to the genus Streptomyces and capable of producing the desired compound and a collection step of collecting the desired compound from the culture produced in the culture step; and others.

IPC Classes  ?

• C12P 17/12 - Nitrogen as only ring hetero atom containing a six-membered hetero ring
• A01N 43/36 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
• A01N 63/02 - Substances produced by, or obtained from, microorganisms or animals
• A01P 3/00 - Fungicides
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61P 31/04 - Antibacterial agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 207/44 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
• C12R 1/465 - Streptomyces

Abstract

This invention relates to solvated and non-solvated crystalline forms of 20,23- dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from)such crystalline forms, methods for making medicaments comprising (or derived from)such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms.

IPC Classes  ?

• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins

Abstract

This invention relates to solvated and non-solvated crystalline forms of 20,23- dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from)such crystalline forms, methods for making medicaments comprising (or derived from)such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms.

IPC Classes  ?

• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins

Abstract

It is intended to provide an excellent antitumor agent which can specifically and effectively inhibit the proliferation of tumor cells in vivo and shows a high safety with little side effect and a medicinal composition which contains the antitumor agent as described above. Namely, an antitumor agent characterized by comprising at least one of a sulfostin-related compound represented by the following general formula (I), a pharmacologically acceptable salt thereof and a hydrate of the same as the active ingredient and a medicinal composition which contains the antitumor agent. General formula (I) wherein n stands for an integer of from 1 to 3.

IPC Classes  ?

• C07D 211/92 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
• A61K 31/664 - Amides of phosphorus acids
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Disclosed is an antibacterial agent having an excellent antibacterial activity against Mycobacterium avium subsp. paratuberculosis. The antibacterial agent has an antibacterial activity against comprises a caprazamycin derivative represented by the general formula (II) or the like. (II) wherein Me represents a methyl group; R1 represents a linear or substantially linear C5-21 alkyl group, a linear or substantially linear C5-21 alkenyl group, a C5-12 cycloalkyl group, or a phenyl group having a linear C1-14 alkyl group, a linear C1-9 alkoxy group or a C5-12 cycloalkyl group at the para-position.

IPC Classes  ?

• A01N 43/62 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms three- or four-membered rings or rings with more than six members
• A01P 3/00 - Fungicides
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61P 31/04 - Antibacterial agents
• C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical

Abstract

This invention relates to a method for making macrolides, and, in particular, to a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl- tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides.

IPC Classes  ?

• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins

Abstract

This invention relates to a method for making macrolides, and, in particular, to a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl- tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides.

IPC Classes  ?

• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins

Abstract

Disclosed are: a novel aminoglycoside antibiotic which has an excellent anti-bacterial activity against an infection-inducing bacterium, particularly MRSA, and also has low renal toxicity; and a process for production of the antibiotic. More specifically, disclosed are: a compound represented by the formula (Ia) or a pharmacologically acceptable salt or solvate thereof, or a diastereomeric mixture of the compound, the salt or the solvate; an antibacterial agent comprising the compound, the salt, the solvate or the diastereomeric mixture; and a process for production of the compound. [Chemical formula 1] (Ia)

IPC Classes  ?

• C07H 15/234 - Cyclohexane rings, substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61P 31/04 - Antibacterial agents

Abstract

The invention provides novel dioctatin derivatives, a process for the production thereof, novel dioctatin derivatives useful as aflatoxin production inhibitor, and a method for controlling aflatoxin pollution by the use of an aflatoxin production inhibitor containing one or more of the dioctatin derivatives. The invention relates to dioctatin derivatives characterized by being represented by the structural formula (I): wherein R1 and R2 are each hydrogen, CH3-(CH2)n-, (CH3)2CH-CH2-, or C6H5-CH2-; n is an integer of 2 to 6; X1 and X2 are each CH3 or hydrogen; and Y is 2-amino-2-butenoic acid or an amino acid residue, with the proviso that the cases wherein both R1 and R2 are CH3-(CH2)4-; X2 is hydrogen; and Y is 2-amino-2-butenoic acid are excepted.

IPC Classes  ?

• C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• A01N 37/46 - N-acyl derivatives
• A01N 43/36 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
• A01P 3/00 - Fungicides
• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• C07C 231/16 - Preparation of optical isomers
• C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
• C07K 5/023 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link in which at least a beta-amino acid is involved

Abstract

Disclosed are: an aflatoxin production inhibitor which can inhibit the production of aflatoxin specifically and effectively and is highly safe and practically useful; a process for producing the inhibitor with good efficiency; and a method for controlling the aflatoxin poisoning using the aflatoxin production inhibitor. An aflatoxin production inhibitor comprising at least one of a dioctane represented by the structural formula (I): (I) wherein R represents a hydrogen or a methyl group, and a derivative thereof as an active ingredient; a process for preparing an aflatoxin production inhibitor by culturing a dioctane-producing bacterium and then performing a method for separation/purification of the aflatoxin production inhibitor from a culture by centrifugal liquid-liquid partition chromatography or by chemical synthesis; and a method for controlling the aflatoxin poisoning comprising inhibiting the production of aflatoxin by an aflatoxin-producing bacterium using the aflatoxin production inhibitor.

IPC Classes  ?

• A01N 37/46 - N-acyl derivatives
• A01N 63/02 - Substances produced by, or obtained from, microorganisms or animals
• A01P 3/00 - Fungicides
• C12P 13/02 - Amides, e.g. chloramphenicol
• C12R 1/465 - Streptomyces

Goods & Services

Proteolytic enzyme.